[Controlled multicentric trial of the antihypertensive agent indapamide].
Two-months' administration of 2.5 mg/day indapamide, preceded and followed by 2 weeks of a placebo, led to a significant fall in pressure values and normalisation of diastolic pressure in a high percentage of 47 subjects, mostly with essential hypertension, in a controlled multi-centre trial. Absence of toxic effects, tolerance and therapeutic activity at low doses recommend the drug for most cases of arterial hypertension.
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007190:Indapamide / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D014882:Water-Electrolyte Balance / Q000187:drug effects
D000959:Antihypertensive Agents; D004232:Diuretics; D010919:Placebos; D007190:Indapamide
Indagine policentrica controllata sull'azione antiipertensiva dell'indapamide.